French study following people with Parkinson’s and related conditions
Part of Brain & nervous system clinical trials.
This study follows people with Parkinson’s disease, certain Parkinson-like conditions, and some people at higher risk. It helps researchers learn how these illnesses start and progress, which may lead to better earlier detection and care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Parkinson’s disease, or a Parkinson-like condition (like MSA or PSP)
- Or you are considered “at risk,” such as a known Parkinson’s gene carrier, an REM sleep disorder, or an early “prodromal” stage
- You are linked to France’s social security system
- You are older than 10 years
- You can and will consent to take part in research
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking to improve how Parkinson’s and related brain conditions are identified and treated sooner. You may be asked to share your health information and provide blood or other samples, and possibly have procedures like a spinal fluid test or a small skin sample.
This study looks at how people with Parkinson’s adapt their movements and how their brain sensorimotor system works. It may help researchers improve understanding of Parkinson’s and refine movement-focused therapies.
This study collects blood and related samples to create a “biobank” and uses lab tests to study genetic risk in Parkinson’s disease and idiopathic REM sleep behavior disorder (RBD). It may help researchers understand why symptoms develop and improve future prevention or treatment approaches.
This study is a registry that collects information from people with Parkinson’s disease to better understand the condition. You may help researchers learn about patterns of symptoms and care over time.
This study is building a large, detailed group of people—some with Parkinson’s and some at higher risk—to understand early changes over time. It uses brain imaging (DaTscan SPECT), sometimes spinal fluid tests (lumbar puncture), and genetic information to help researchers better measure disease and develop future treatments.
This is an observational study, meaning it doesn’t test a new drug—researchers mainly follow people to better understand moderate Parkinson’s disease and who may be good candidates for future cell therapy. If you have moderate symptoms that aren’t well controlled with tablets, this study may help inform better future treatments.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.